阿帕替尼联合GP方案化学治疗晚期肺癌患者的近期临床效果及对血清肿瘤标志物的影响

The Short-term Clinical Efficacy of Apatinib Combined with GP Regimen in the Treatment of Patients with Advanced Lung Cancer and Its Influence on Serum Tumor Markers

目的探讨阿帕替尼联合GP方案化学治疗晚期肺癌患者的近期临床效果及对血清肿瘤标志物的影响。方法选取晚期肺癌88例作为研究对象,将其中阿帕替尼联合GP方案化学治疗的44例作为观察组,单纯应用GP方案化学治疗的44例作为对照组,观察比较两组临床疗效,治疗前后血清肿瘤标志物鳞状细胞癌抗原(SCCA)、细胞角蛋白19片段(CYERA21-1)、癌胚抗原(CEA)水平及不良反应发生情况。结果观察组总有效率为72.73%,对照组总有效率为54.55%,观察组总有效率明显高于对照组,差异有统计学意义(P<0.05)。治疗后观察组和对照组SCCA、CYERA21-1和CEA水平均较治疗前明显下降;观察组SCCA、CYERA21-1及CEA水平均较对照组降低,差异具有统计学意义(P<0.05)。观察组不良反应总发生率为22.73%,对照组不良反应总发生率为50.00%,观察组不良反应总发生率明显低于对照组,差异具有统计学意义(P<0.05)。结论阿帕替尼联合GP方案化学治疗晚期肺癌患者临床效果显著,能够降低肿瘤标志物SCCA、CYERA21-1、CEA水平,且安全可靠。

Objective To investigate the short-term clinical efficacy of apatinib combined with GP regimen in the treatment of patients with advanced lung cancer and its influence on serum tumor markers.Methods Eighty-eight patients with advanced lung cancer were selected as study subjects.Of them,44 patients who were treated with apatinib combined with GP regimen were selected as observation group,and 44 patients who were treated with GP regimen alone were selected as control group.The clinical efficacy,serum tumor markers SCCA,CYERA21-1,and CEA levels before and after treatment,and incidence of adverse reactions were observed and compared between the two groups.Results The total effective rate was 72.73%in the observation group,which was significantly higher than that(54.55%)in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of SCCA,CYERA21-1,and CEA in the observation group and the control group were significantly lower than those before treatment;the levels of SCCA,CYERA21-1,and CEA in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The total incidence of adverse reactions was 22.73%in the observation group,which was remarkably lower than 50.00%in the control group,with a significant difference(P<0.05).Conclusion Apatinib combined with GP regimen have significant clinical efficacy in the treatment of advanced lung cancer,which can reduce the levels of tumor markers SCCA,CYERA21-1,CEA,showing good safety and reliability.